Pancreatic CancerNCT07591480
Barriers And Facilitators To Clinical Trial Enrollment: A Qualitative Study Of Pancreatic Cancer Patients
An observational study of Pancreatic Cancer, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
The purpose of this research is to understand why some groups of people do not join clinical trials as much as others. These groups can include people from different racial or ethnic backgrounds, people with lower incomes, people who live in rural areas, and people who speak different languages. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pancreatic Cancer
- What is being tested?
- Interviews
- How many people
- 20 participants
- Where
- 1 siteUnited States
- Study dates
- 1 May 2026to 1 Oct 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: UT MD Anderson
Who may be able to join
- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Males and females; Age ≥18
- Documented diagnosis of pancreatic cancer
- Access to necessary resources for participating in a technology-based intervention (i.e., computer, smartphone, internet access)
Who cannot join
- An individual who meets any of the following criteria will be excluded from participation in this study:
- Patients who speak a primary language other than English or Spanish
- Patients who are cognitively impaired
- Pregnant women
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
UT MD Anderson
Houston, Texas, 77030
Rebecca A Snyder, MD, MPH, 713-792-0036, rsnyder@mdanderson.org
Rebecca A Snyder, MD, MPH
About this study
The purpose of this research is to understand why some groups of people do not join clinical trials as much as others. These groups can include people from different racial or ethnic backgrounds, people with lower incomes, people who live in rural areas, and people who speak different languages. Investigators interview participants to learn about their experiences with clinical trials. By learning from them, investigators hope to find better ways to help more people learn about, join, and stay in clinical trials so that research is fair and helpful for everyone.
Read the detailed description
Primary Objectives:
The primary objective of this study is to comprehensively assess the barriers to and facilitators of interventional clinical trial enrollment via in-depth interview of participants with pancreatic cancer among diverse backgrounds. The primary outcome will be identification of specific opportunities for improvement to increase study enrollment.
The above aim is part of a long-term multi-armed quality improvement project with the goal of increasing clinical trial enrollment among minority individuals with pancreas cancer. Using the data gained from this project, investigators aim to implement and tailor interventions towards addressing these barriers in conjunction with current scientific evidence. While the QI project is separate from this IRB submission, data gained from this specific research study will be crucial towards steering further improvement efforts.
- Conditions
- Pancreatic Cancer
- Being tested
- Interviews
- Medical subject headings
- Pancreatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
InterviewsOther
Participants will be offered a 30 to 45-minute telephone or video in-depth interview at a specific time convenient to the participants.
| Study group | Role | What they receive |
|---|---|---|
| All patients | Participants will be sampled using pre-selected demographic, geographic, and clinical characteristics, allowing for purposive sampling among patients with characteristics where disparities are known to exist. Receives: Other: Interviews |
What is being measured
The primary outcome is the main question the study is designed to answer.
Questionnaires/Surveys
Identification of specific opportunities for improvement to increase study enrollment.
Measured: Through study completion; an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 May 2026
- Study start1 May 2026 (estimated)
- Primary completion1 Oct 2026 (estimated)
- Study completion1 Oct 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pancreatic CancerStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Rebecca A Snyder, MD, MPH, Principal investigator, UT MD Anderson
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07591480
- Sponsor's protocol ID
- 2026-0019
- Other IDs
- NCI-2026-02708
- Status last verified
- May 2026
- First submitted
- 8 Apr 2026
- Last updated
- 15 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Barriers And Facilitators To Clinical Trial Enrollment: A Qualitative Study Of Pancreatic Cancer Patients
- ClinicalTrials.gov ID
- NCT07591480
- Acronym / sponsor ID
- 2026-0019
- Conditions
- Pancreatic Cancer
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Study start
- 1 May 2026 (estimated)
- Primary completion
- 1 Oct 2026 (estimated)
- Study completion
- 1 Oct 2028 (estimated)
- First posted
- 15 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this research is to understand why some groups of people do not join clinical trials as much as others. These groups can include people from different racial or ethnic backgrounds, people with lower incomes, people who live in rural areas, and people who speak different languages. Investigators interview participants to learn about their experiences with clinical trials. By learning from them, investigators hope to find better ways to help more people learn about, join, and stay in clinical trials so that research is fair and helpful for everyone.
Detailed description
Primary Objectives:
The primary objective of this study is to comprehensively assess the barriers to and facilitators of interventional clinical trial enrollment via in-depth interview of participants with pancreatic cancer among diverse backgrounds. The primary outcome will be identification of specific opportunities for improvement to increase study enrollment.
The above aim is part of a long-term multi-armed quality improvement project with the goal of increasing clinical trial enrollment among minority individuals with pancreas cancer. Using the data gained from this project, investigators aim to implement and tailor interventions towards addressing these barriers in conjunction with current scientific evidence. While the QI project is separate from this IRB submission, data gained from this specific research study will be crucial towards steering further improvement efforts.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| All patients | – | Other: InterviewsParticipants will be sampled using pre-selected demographic, geographic, and clinical characteristics, allowing for purposive sampling among patients with characteristics where disparities are known to exist. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- UT MD Anderson
Key inclusion criteria (5 listed)
- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Males and females; Age ≥18
- Documented diagnosis of pancreatic cancer
- Access to necessary resources for participating in a technology-based intervention (i.e., computer, smartphone, internet access)
Key exclusion criteria (4 listed)
- An individual who meets any of the following criteria will be excluded from participation in this study:
- Patients who speak a primary language other than English or Spanish
- Patients who are cognitively impaired
- Pregnant women
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| InterviewsParticipants will be offered a 30 to 45-minute telephone or video in-depth interview at a specific time convenient to the participants. | Other | All patients |
Primary outcome
Questionnaires/Surveys
Time frame: Through study completion; an average of 1 year
Identification of specific opportunities for improvement to increase study enrollment.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 May 2026.
- UT MD Anderson WebsiteLink provided by the sponsor.
Related trials for Pancreatic Cancer
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingPhase 1
Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingPhase 3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer, Pancreatic Cancer Metastatic
RecruitingPhase 3
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
Pancreatic Carcinoma, Pancreatic Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Rebecca A Snyder, MD, MPH principal investigator
UT MD Anderson
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pancreatic Cancer, run by M.D. Anderson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 15 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Rebecca A Snyder, MD, MPH ((713) 792-0036, rsnyder@mdanderson.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Questionnaires/Surveys (time frame: Through study completion; an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2026.